Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Biotherapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-16.14	-140.04	-262.14	-311.46	-206.36
Depreciation & Amortization	4.67	1.96	0.75	0.93	0.45
Stock-Based Compensation	40.36	41.73	38.81	32.68	23.89
Other Adjustments	0.31	-0.73	-0.98	30.3	3.76
Change in Receivables	-73.16	-47.26	-17.35	-8.46	-
Changes in Inventories	-7.33	-0.4	-5.62	-7.51	-
Changes in Accounts Payable	-1.69	2.23	3.15	1.57	0.25
Changes in Accrued Expenses	50.04	32.03	5.59	1.19	10.46
Changes in Other Operating Activities	-2.69	-1.68	-9.28	3.04	-7.09
Operating Cash Flow	-5.63	-112.16	-247.06	-257.72	-174.63
Capital Expenditures	-0.69	-0.14	-0.43	-0.33	-1
Purchases of Intangible Assets	-10	-5	-	-22.95	-
Purchases of Investments	-246.99	-254.82	-225.84	-415.39	-292.51
Proceeds from Sale of Investments	227.42	288.78	406.5	351.47	217.55
Investing Cash Flow	-30.25	28.82	180.23	-87.2	-75.95
Long-Term Debt Issued	-	-	-	125	73.99
Long-Term Debt Repaid	-	-100	-	-	-
Net Long-Term Debt Issued (Repaid)	-	-100	-	125	73.99
Issuance of Common Stock	6.97	166.2	101.32	178.99	209.6
Net Common Stock Issued (Repurchased)	6.97	166.2	101.32	178.99	209.6
Other Financing Activities	-	-	-	-2.19	-1.64
Financing Cash Flow	6.97	66.2	101.32	301.8	281.95
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.17	-0.24	-0.05	-	-
Net Cash Flow	-28.74	-17.37	34.45	-43.12	31.37
Free Cash Flow	-6.31	-112.3	-247.49	-258.05	-175.62
FCF Margin	-1.68%	-57.14%	-415.20%	-7000.76%	-
Free Cash Flow Per Share	-0.05	-0.93	-3.57	-4.69	-3.55
Levered Free Cash Flow	26.17	-206.04	-267.97	-187.57	-129.29
Unlevered Free Cash Flow	29.13	-95	-249.83	-302.74	-203.45

Updated Feb 25, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q